---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-091736"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:04:18.575385+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged

## Summary
- Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).
- SUBLOCADE NR $176M (-2% YoY); FY 2025 guidance unchanged at $725M-$765M.
- GAAP diluted EPS $0.38 (down 15%); non-GAAP diluted EPS $0.41 (down 2%).
- SG&A $132M (-8% YoY non-GAAP) reflects cost savings; FY non-GAAP SG&A guided $525M-$535M.
- Revised prior financials to correct Branded Fee accrual (immaterial $6M overstatement in 2024).

## SEC filing metadata
- accession: 0001193125-25-091736
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/0001193125-25-091736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-091736
- JSON: https://secwatch.observer/filing/0001193125-25-091736.json
- Plain text: https://secwatch.observer/filing/0001193125-25-091736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.